Evaluating Serum Endosialin (CD248) Levels as a Diagnostic Marker in Gestational Diabetes
A Case-Control Study
DOI:
https://doi.org/10.15605/jafes.040.02.13Keywords:
CD248, endosialin, gestational diabetes mellitus, inflammation, OGTTAbstract
Objectives. Gestational diabetes mellitus (GDM), a pregnancy-induced hyperglycemia, affects approximately 17% of pregnancies globally. Its pathophysiology remains unclear, with inflammation and vascular remodeling playing key roles. CD248, a glycoprotein linked to inflammation and vascular remodeling, has been implicated in various conditions, but its role in GDM is uncertain.
Methodology. A prospective case-control study was conducted with 169 pregnant women aged 18 to 49 at a tertiary hospital. Serum CD248 levels were assessed at 24 to 28 weeks of gestation prior to the oral glucose tolerance test (OGTT). Statistical analyses evaluated the association between CD248 levels, BMI and GDM status.
Results. Of the participants, 32 (18.9%) were diagnosed with GDM. CD248 levels were lower in GDM patients (8.15 ± 10.16 ng/mL) than in controls (11.42 ± 15.44 ng/mL), but the difference was not statistically significant (p = 0.084). Although CD248 levels did not correlate with OGTT values, it was positively associated with BMI (p <0.001).
Conclusion. Unlike earlier findings associating elevated CD248 levels with early pregnancy GDM risk, this study found no significant relationship during later gestational stages. These results highlight a potentially complex and context-dependent role for CD248 in GDM pathophysiology.
Downloads
References
1. International Association of Diabetes and Pregnancy Study Groups Consensus Panel; Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676-82. https://pubmed.ncbi.nlm.nih.gov/20190296 https://pmc.ncbi.nlm.nih.gov/articles/PMC2827530 https://doi.org/10.2337/dc09-1848 DOI: https://doi.org/10.2337/dc09-1848
2. Simmons D, Immanuel J, Hague WM, et al. Treatment of gestational diabetes mellitus diagnosed early in pregnancy. N Engl J Med. 2023;388(23):2132-44. https://pubmed.ncbi.nlm.nih.gov/37144983 https://doi.org/10.1056/NEJMoa2214956 DOI: https://doi.org/10.1056/NEJMoa2214956
3. Lowe LP, Perak AM, Kuang A, et al. Associations of glycemia and lipid levels in pregnancy with dyslipidemia 10-14 years later: The HAPO follow-up study. Diabetes Res Clin Pract. 2022;185:109790. https://pubmed.ncbi.nlm.nih.gov/35192911 https://pmc.ncbi.nlm.nih.gov/articles/PMC9210945 https://doi.org/10.1016/j.diabres.2022.109790 DOI: https://doi.org/10.1016/j.diabres.2022.109790
4. Bardugo A, Bendor CD, Rotem RS, et al. Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study. Lancet Diabetes Endocrinol. 2023;11(5):333-44. https://pubmed.ncbi.nlm.nih.gov/37011646 https://doi.org/10.1016/S2213-8587(23)00062-1 DOI: https://doi.org/10.1016/S2213-8587(23)00062-1
5. Pantham P, Aye IL, Powell TL. Inflammation in maternal obesity and gestational diabetes mellitus. Placenta. 2015;36(7):709-15. https://pubmed.ncbi.nlm.nih.gov/25972077 https://pmc.ncbi.nlm.nih.gov/articles/PMC4466145 https://doi.org/10.1016/j.placenta.2015.04.006 DOI: https://doi.org/10.1016/j.placenta.2015.04.006
6. Kim KJ, Cho CS, Kim WU. Role of placenta growth factor in cancer and inflammation. Exp Mol Med. 2012;44(1):10-9. https://pubmed.ncbi.nlm.nih.gov/22217448 https://pmc.ncbi.nlm.nih.gov/articles/PMC3277893 https://doi.org/10.3858/emm.2012.44.1.023 DOI: https://doi.org/10.3858/emm.2012.44.1.023
7. Vrachnis N, Belitsos P, Sifakis S, et al. Role of adipokines and other inflammatory mediators in gestational diabetes mellitus and previous gestational diabetes mellitus. Int J Endocrinol. 2012;2012:549748. https://pubmed.ncbi.nlm.nih.gov/22550485 https://pmc.ncbi.nlm.nih.gov/articles/PMC3328961 https://doi.org/10.1155/2012/549748 DOI: https://doi.org/10.1155/2012/549748
8. Akarsu S, Bagirzade M, Omeroglu S, Büke B. Placental vascularization and apoptosis in Type-1 and gestational DM. J Matern Fetal Neonatal Med. 2017;30(9):1045-50. https://pubmed.ncbi.nlm.nih.gov/27279012 https://doi.org/10.1080/14767058.2016.1199676 DOI: https://doi.org/10.1080/14767058.2016.1199676
9. Naylor AJ, Azzam E, Smith S, et al. The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice. Arthritis Rheum. 2012;64(10):3334-43. https://pubmed.ncbi.nlm.nih.gov/22674221
https://pmc.ncbi.nlm.nih.gov/articles/PMC4209224 https://doi.org/10.1002/art.34556 DOI: https://doi.org/10.1002/art.34556
10. Teicher BA. CD248: A therapeutic target in cancer and fibrotic diseases. Oncotarget. 2019;10(9):993-1009. https://pubmed.ncbi.nlm.nih.gov/30847027
https://pmc.ncbi.nlm.nih.gov/articles/PMC6398180 https://doi.org/10.18632/oncotarget.26590 DOI: https://doi.org/10.18632/oncotarget.26590
11. Ohradanova A, Gradin K, Barathova M, et al. Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. Br J Cancer. 2008;99(8):1348-56. https://pubmed.ncbi.nlm.nih.gov/18813310
https://pmc.ncbi.nlm.nih.gov/articles/PMC2570523 https://doi.org/10.1038/sj.bjc.6604685 DOI: https://doi.org/10.1038/sj.bjc.6604685
12. Hasanov Z, Ruckdeschel T, König C, et al. Endosialin promotes atherosclerosis through phenotypic remodeling of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2017;37(3):495-505. https://pubmed.ncbi.nlm.nih.gov/28126825 https://doi.org/10.1161/ATVBAHA.116.308455 DOI: https://doi.org/10.1161/ATVBAHA.116.308455
13. Mogler C, Wieland M, König C, et al. Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage. EMBO Mol Med. 2015;7(3):332-8. https://pubmed.ncbi.nlm.nih.gov/25680861
https://pmc.ncbi.nlm.nih.gov/articles/PMC4364949 https://doi.org/10.15252/emmm.201404246 DOI: https://doi.org/10.15252/emmm.201404246
14. Petrus P, Fernandez TL, Kwon MM, et al. Specific loss of adipocyte CD248 improves metabolic health via reduced white adipose tissue hypoxia, fibrosis and inflammation. EBioMedicine. 2019;44:489-501. https://pubmed.ncbi.nlm.nih.gov/31221584
https://pmc.ncbi.nlm.nih.gov/articles/PMC6606747 https://doi.org/10.1016/j.ebiom.2019.05.057 DOI: https://doi.org/10.1016/j.ebiom.2019.05.057
15. Wei Y, He A, Huang Z, Liu J, Li R. Placental and plasma early predictive biomarkers for gestational diabetes mellitus. Proteomics Clin Appl. 2022;16(4):e2200001. https://pubmed.ncbi.nlm.nih.gov/35385222 https://doi.org/10.1002/prca.202200001 DOI: https://doi.org/10.1002/prca.202200001
16. Benedet PO, Safikhan NS, Pereira MJ, et al. CD248 promotes insulin resistance by binding to the insulin receptor and dampening its insulin-induced autophosphorylation. EBioMedicine. 2024;99:104906. https://pubmed.ncbi.nlm.nih.gov/38061240
https://pmc.ncbi.nlm.nih.gov/articles/PMC10750038 https://doi.org/10.1016/j.ebiom.2023.104906 DOI: https://doi.org/10.1016/j.ebiom.2023.104906
17. Zhang Q, Lu C, Lu F, Liao Y, Cai J, Gao J. Challenges and opportunities in obesity: the role of adipocytes during tissue fibrosis. Front Endocrinol (Lausanne). 2024;15:1365156. https://pubmed.ncbi.nlm.nih.gov/38686209
https://pmc.ncbi.nlm.nih.gov/articles/PMC11056552 https://doi.org/10.3389/fendo.2024.1365156 DOI: https://doi.org/10.3389/fendo.2024.1365156
18. Patrick K, Tian X, Cartwright D, et al. Sex-specific effects of CD248 on metabolism and the adipose tissue lipidome. PLoS One. 2023;18(4):e0284012. https://pubmed.ncbi.nlm.nih.gov/37115796
https://pmc.ncbi.nlm.nih.gov/articles/PMC10146461 https://doi.org/10.1371/journal.pone.0284012 DOI: https://doi.org/10.1371/journal.pone.0284012
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Tevfik Berk BILDACI, Can, Ufuk, Aytuğ, Selcuk
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
